Researchers at Novartis say that after three years of therapy in an ongoing Phase II study, the oral FTY720 demonstrated positive results for patients with multiple sclerosis. Data demonstrate that 73 percent of patients who began the study on FTY720 5 mg remained free from relapses after three years. Release